NEW HAVEN, Conn., Sept. 30, 2015 /PRNewswire/ -- Arvinas LLC ("Arvinas") today announced that it has been named byFierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Arvinas is harnessing the body's own natural quality control system to target and degrade pathogenic proteins by using bifunctional small molecules, Proteolysis-Targeting Chimeras (PROTACs). PROTACs recruit an E3 ubiquitin ligase to a specific targeted protein labeling that protein for elimination by the Ubiquitin/Proteasome System.
Manuel Litchman, President and Chief Executive Officer of Arvinas, commented: "We are thrilled to be selected by FierceBiotech to be among the top private biotech firms globally. This award recognizes the dedication of our employees, our founder, Dr. Craig Crews, and our partners to bring our PROTAC technologies to patients with difficult to treat diseases."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's thirteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online atwww.fiercebiotech.com/fierce15.
An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals,FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Arvinas
Arvinas is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients. To address these pathological intracellular proteins, Arvinas is developing a new drug paradigm based on the elimination of these proteins. Our innovative protein degradation technology uses small molecule drugs to "tag" specific proteins to be degraded by the ubiquitin/proteasome system (UPS), which is responsible for the normal turnover of most proteins within the cell.
Based on groundbreaking research conducted at Yale University by our Founder and Chief Scientific Advisor, Craig Crews, PhD, Arvinas has developed a platform technology to induce the loss of intracellular proteins: Proteolysis-Targeting Chimera (PROTAC). The ability of PROTAC-based drugs to induce protein degradation (instead of protein inhibition) offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands our ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.
CONTACTS:
Rebecca Friend
FierceBiotech
202-824-5050
[email protected]
Arvinas Media Contact
Carolyn Hawley
[email protected]